US2019062445A1PendingUtilityA1

Fully human antibodies against human 4-1bb

66
Assignee: BRISTOL MYERS SQUIBB COPriority: Oct 10, 2003Filed: Sep 20, 2018Published: Feb 28, 2019
Est. expiryOct 10, 2023(expired)· nominal 20-yr term from priority
A61P 35/00A61K 39/39C07K 2317/75C07K 16/2878A61K 2039/53A61K 39/12C07K 2317/33C07K 16/30C12N 2740/15034C07K 2317/21C07K 2317/515C07K 2317/565C07K 2317/92A61K 2039/55516C07K 2317/51A61K 2039/505A61K 2300/00A61K 39/0011A61K 2039/876A61K 2039/884C07K 2317/54C07K 2317/55A61P 21/04A61P 19/02A61K 39/00C07K 16/28
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A monoclonal antibody or antigen-binding portion thereof that specifically binds to 4-1BB, comprising a light chain variable region and a heavy chain variable region, wherein:
 said light chain variable region comprises a CDR1, a CDR2, and a CDR3 as depicted in  FIG. 4 ; and   said heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 as depicted in  FIG. 3 .   
     
     
         2 . The monoclonal antibody or antigen-binding portion thereof of  claim 1 , wherein:
 said light chain comprises a variable region as depicted in  FIG. 4 ; and   said heavy chain comprises a variable region as depicted in  FIG. 3 .   
     
     
         3 . A monoclonal antibody comprising a light chain and a heavy chain, wherein said light chain comprises amino acid residues 21-236 of SEQ ID NO:6 and said heavy chain comprises amino acid residues 20-467 of SEQ ID NO:3. 
     
     
         4 . A pharmaceutical composition comprising:
 the monoclonal antibody or antigen-binding portion thereof of  claim 1 ; and   a pharmaceutically acceptable carrier.   
     
     
         5 . A pharmaceutical composition comprising:
 the monoclonal antibody of  claim 3 ; and   a pharmaceutically acceptable carrier.   
     
     
         6 . A method for treating a cancer in a subject comprising administering a therapeutically effective amount of the monoclonal antibody or antigen-binding portion thereof of  claim 1  to said subject. 
     
     
         7 . An isolated polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of amino acid residues 20-467 of SEQ ID NO:3. 
     
     
         8 . The polynucleotide of  claim 7  that comprises the nucleotide sequence of SEQ ID NO:1. 
     
     
         9 . An isolated polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of amino acid residues 21-236 of SEQ ID NO:6. 
     
     
         10 . The polynucleotide of  claim 9  that comprises the nucleotide sequence of SEQ ID NO:4.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.